Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Incyte entered a clinical collaboration with Natera for a Phase II study of INCA33890, its investigational bispecific immunotherapy, in stage 2/3 colorectal cancer patients who completed surgery and adjuvant chemotherapy. Patients will undergo longitudinal Signatera MRD testing for up to 12 months, and those who test MRD-positive without radiographic disease may enroll and receive treatment — a treatment-on-MRD (TOMR) design.
Key figures
- Drug Name
- INCA33890
- Phase Of Trial
- Phase II
- Trial indication
- stage 2/3 colorectal cancer after surgery and adjuvant chemotherapy
- Signatera testing duration
- up to 12 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.